“The analysis of NEW-HOPE, Quantum Genomics’ Phase IIb study of firibastat in hypertension, has demonstrated that firibastat does not negatively impact renal function. This study aims to confirm that firibastat could potentially be used to treat hypertension, in particular, treatment-resistant hypertension or heart failure, even in the case of associated renal failure,” said Bruno Besse, M.D., Chief Medical Officer of Quantum Genomics. A drug that can be used even in the case of associated renal failure represents a real benefit for managing hypertensive patients or those with heart failure. If the results of this study are positive, the market for firibastat would be considerably expanded.
